NASDAQ
13.54USD
-0.01 (-0.07%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
2.49
52W range
3.97-15.4
Day range
13.27–14.08
Open
13.51
Prev close
13.55
Volume
3.4M
Avg volume
4.4M
Dividend
0.00
IPO
2020-09-18
https://seekingalpha.com/article/4926541-compass-pathways-the-psilocybin-biotech-leader-with-strong-momentum · 7/28/2026+0.90
https://www.benzinga.com/trading-ideas/movers/26/07/60489096/why-jb-hunt-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket · 7/16/2026+0.80
https://www.proactiveinvestors.com/companies/news/1095518 · 7/15/2026+0.60
https://www.marketbeat.com/instant-alerts/compass-pathways-eyes-2027-launch-as-psilocybin-depression-data-holds-up-2026-07-10/ · 7/10/2026+0.80
https://www.businesswire.com/news/home/20260702092582/en/Compass-Pathways-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4/ · 7/2/2026+0.00
https://www.globenewswire.com/news-release/2026/06/02/3304871/0/en/fundamental-pharma-appoints-depression-drug-developer-dr-hans-eriksson-as-chief-medical-officer-to-advance-its-lead-treatment-resistant-depression-candidate.html · 6/2/2026+0.00
https://www.youtube.com/watch?v=GAEpfWNOPFY · 6/1/2026+1.00
https://seekingalpha.com/article/4904981-compass-pathways-imminent-commercialization-should-provide-further-upside · 5/15/2026+0.90
https://seekingalpha.com/article/4894631-trump-psychedelics-stance-reignites-sector-how-investors-can-benefit · 4/27/2026+1.00
https://www.fool.com/investing/2026/04/23/trump-backs-psychedelics-heres-1-company-investors/ · 4/24/2026+1.00
https://www.businesswire.com/news/home/20260418890886/en/Compass-Pathways-Commends-White-House-Executive-Order-to-Accelerate-Research-and-Access-for-Psychedelic-Treatments/ · 4/18/2026+0.60
https://www.proactiveinvestors.com/companies/news/1086038 · 1/21/2026+0.60
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
